Browse studies

Find your next paid study

4 recruiting studies matching your filters

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2 - 17 Years With Moderately to Severely Active Ulcerative Colitis

This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pedia…

Moderately to Severely Active Ulcerative Colitis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Hoffmann-La RocheNCT07158242

Phase 1

A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by t…

Active Ulcerative Colitis

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Hoffmann-La RocheNCT07665723

Phase 1

A Randomized, Open-label, Pilot Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis

The study is to evaluate the safety, feasibility, and preliminary efficacy of frozen FMT delivery via retention enema compared to lyophilized powder given in o…

Active Ulcerative Colitis (UC)

Estimated

~$150 – $3,000

Actual pay is set by the research site.

The University of Texas Health Science Center, HoustonNCT05786404

Phase 3

A Phase III, Multicenter, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Patients With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to assess the efficacy and safety of subcutaneous induction with afimkibart in participants with moderately to severely active ulc…

Moderately to Severely Active Ulcerative Colitis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Hoffmann-La RocheNCT07846683